TRDA vs. VERA, AMRX, RCKT, CPRX, GLPG, AGIO, PTGX, ZLAB, KROS, and GPCR
Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Vera Therapeutics (VERA), Amneal Pharmaceuticals (AMRX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Zai Lab (ZLAB), Keros Therapeutics (KROS), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical preparations" industry.
Entrada Therapeutics (NASDAQ:TRDA) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.
Entrada Therapeutics has a net margin of 14.42% compared to Vera Therapeutics' net margin of 0.00%. Entrada Therapeutics' return on equity of 9.73% beat Vera Therapeutics' return on equity.
In the previous week, Vera Therapeutics had 5 more articles in the media than Entrada Therapeutics. MarketBeat recorded 7 mentions for Vera Therapeutics and 2 mentions for Entrada Therapeutics. Vera Therapeutics' average media sentiment score of 0.87 beat Entrada Therapeutics' score of 0.59 indicating that Vera Therapeutics is being referred to more favorably in the news media.
Vera Therapeutics received 13 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 54.55% of users gave Vera Therapeutics an outperform vote.
Entrada Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 31.99%. Vera Therapeutics has a consensus price target of $36.71, suggesting a potential downside of 4.29%. Given Entrada Therapeutics' higher possible upside, equities research analysts plainly believe Entrada Therapeutics is more favorable than Vera Therapeutics.
Entrada Therapeutics has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
Entrada Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by insiders. Comparatively, 21.7% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Entrada Therapeutics beats Vera Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Entrada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entrada Therapeutics Competitors List
Related Companies and Tools
